Torsdag 29 Maj | 09:26:12 Europe / Stockholm

Prenumeration

2025-05-27 11:52:00

Chordate Medical’s first quarter of 2025 was marked by scientific validation, strategic financing, and continued international expansion. Sales more than doubled compared to the same period last year, although still at a relatively low level. BioStock reached out to CEO Anders Weilandt to learn more.

Read the article at biostock.se

https://biostock.se/en/2025/05/chordate-medicals-ceo-comments-on-the-quarterly-report/